37.93
Cytokinetics Inc stock is traded at $37.93, with a volume of 1.88M.
It is down -3.93% in the last 24 hours and down -16.51% over the past month.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
See More
Previous Close:
$39.48
Open:
$38.9
24h Volume:
1.88M
Relative Volume:
1.00
Market Cap:
$4.55B
Revenue:
$18.47M
Net Income/Loss:
$-589.53M
P/E Ratio:
-7.211
EPS:
-5.26
Net Cash Flow:
$-399.80M
1W Performance:
-4.72%
1M Performance:
-16.51%
6M Performance:
-29.51%
1Y Performance:
-43.85%
Cytokinetics Inc Stock (CYTK) Company Profile
Name
Cytokinetics Inc
Sector
Industry
Phone
(650) 624-3000
Address
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
CYTK
Cytokinetics Inc
|
37.93 | 4.55B | 18.47M | -589.53M | -399.80M | -5.26 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-07-25 | Initiated | Citigroup | Buy |
Jan-22-25 | Initiated | Stifel | Buy |
Nov-08-24 | Initiated | RBC Capital Mkts | Outperform |
Aug-13-24 | Downgrade | Goldman | Buy → Neutral |
Jan-24-24 | Downgrade | UBS | Buy → Neutral |
Jan-05-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Nov-09-23 | Initiated | Goldman | Buy |
Nov-07-23 | Initiated | B. Riley Securities | Buy |
Aug-15-23 | Initiated | SVB Securities | Outperform |
Feb-17-23 | Initiated | BofA Securities | Neutral |
Dec-23-22 | Reiterated | Needham | Buy |
Dec-20-22 | Initiated | Truist | Buy |
Oct-11-22 | Initiated | UBS | Buy |
Jan-28-22 | Initiated | Goldman | Buy |
Dec-22-21 | Initiated | Oppenheimer | Outperform |
Dec-10-21 | Initiated | JP Morgan | Overweight |
Oct-07-21 | Initiated | Jefferies | Buy |
Mar-12-21 | Initiated | Wolfe Research | Outperform |
Feb-18-21 | Initiated | Barclays | Overweight |
Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
Oct-29-20 | Initiated | Goldman | Neutral |
Jul-10-20 | Initiated | Raymond James | Strong Buy |
May-05-20 | Initiated | Mizuho | Buy |
Apr-09-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
Sep-10-18 | Resumed | Morgan Stanley | Equal-Weight |
Nov-22-17 | Reiterated | Morgan Stanley | Overweight |
Nov-22-17 | Downgrade | Needham | Strong Buy → Buy |
Nov-21-17 | Reiterated | H.C. Wainwright | Buy |
Jul-31-17 | Initiated | Morgan Stanley | Overweight |
Mar-08-17 | Initiated | Rodman & Renshaw | Buy |
Feb-06-17 | Upgrade | Needham | Buy → Strong Buy |
Dec-16-16 | Initiated | Cantor Fitzgerald | Overweight |
Jul-28-16 | Reiterated | Needham | Buy |
Nov-10-15 | Reiterated | FBR Capital | Outperform |
Nov-09-15 | Reiterated | ROTH Capital | Buy |
Jul-24-15 | Reiterated | MLV & Co | Buy |
Dec-31-14 | Reiterated | ROTH Capital | Buy |
Nov-04-14 | Upgrade | MLV & Co | Hold → Buy |
Apr-28-14 | Reiterated | Needham | Buy |
View All
Cytokinetics Inc Stock (CYTK) Latest News
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach - Benzinga
Bristol Myers' Camzyos Update Boosts Prospects for Cytokinetics (CYTK) | BMY Stock News - GuruFocus
Stifel maintains Cytokinetics stock buy rating, $87 target By Investing.com - Investing.com India
US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble - insights.citeline.com
Is Cytokinetics Inc. (NASDAQ:CYTK) the Best High Short Interest Stock to Buy Now? - Yahoo
10 Best High Short Interest Stocks to Buy Now - Insider Monkey
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics Strategic Talent Push: 13 New Hires Receive Major Equity Package Worth $3.9M - Stock Titan
Cytokinetics director John Henderson sells $123,325 in stock By Investing.com - Investing.com South Africa
Cytokinetics director John Henderson sells $123,325 in stock - Investing.com Australia
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It - MSN
Cytokinetics (CYTK) Gains Favor as Key Trial by Bristol-Myers Fa - GuruFocus
Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten - insights.citeline.com
JMP maintains $78 target on Cytokinetics stock after trial update By Investing.com - Investing.com Canada
Cytokinetics falls after rival Bristol Myers' heart drug fails trial - TradingView
BofA Adjusts Price Target for Cytokinetics (CYTK) Amid Competiti - GuruFocus
Bristol Myers stumbles in bid to widen heart drug’s use - Yahoo Finance
Citi Analysts Include Cytokinetics (CYTK) in 2025 North America Focus List | CYTK Stock News - GuruFocus
Cytokinetics, IncorporatedCommon Stock (NQ: CYTK - FinancialContent
Cytokinetics CEO Robert Blum sells $183,850 in stock By Investing.com - Investing.com South Africa
Cytokinetics CEO Robert Blum sells $183,850 in stock - Investing.com Australia
Cytokinetics rises as Edgewise posts mid-stage trial data for heart disorder therapy - MSN
JMP reiterates Cytokinetics stock with $78 target on HCM trial optimism - Investing.com Canada
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO - GlobeNewswire
Exclusive: Cardiometabolic biotech gets $57.5M Series B, with help from Cytokinetics - Endpoints News
Optimistic Buy Rating on Cytokinetics Driven by Promising Aficamten Trial Outcomes - TipRanks
Cytokinetics stock plunges to 52-week low of $33.67 By Investing.com - Investing.com Canada
Cytokinetics’ CK-4021586 improves cardiac function in HFpEF - BioWorld MedTech
Cytokinetics (NASDAQ:CYTK) Given "Buy" Rating at HC Wainwright - MarketBeat
Cytokinetics EVP sells $72,360 in stock By Investing.com - Investing.com South Africa
Cytokinetics EVP sells $72,360 in stock - Investing.com Australia
Cytokinetics' SWOT analysis: aficamten potential drives stock outlook - Investing.com
Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health By Investing.com - Investing.com Canada
Cytokinetics CCO Andrew Callos sells $103k in stock By Investing.com - Investing.com India
Cytokinetics CCO Andrew Callos sells $103k in stock - Investing.com
Cytokinetics at Needham Conference: Strategic Moves in Cardiovascular Health - Investing.com
Cytokinetics director Robert Harrington sells shares worth $17,743 By Investing.com - Investing.com South Africa
Cytokinetics director Robert Harrington sells shares worth $17,743 - Investing.com Australia
H.C. Wainwright maintains $120 target on Cytokinetics stock By Investing.com - Investing.com Canada
Cytokinetics stock holds $78 target from JMP amid trial results By Investing.com - Investing.com Canada
Cantor Fitzgerald maintains overweight on Cytokinetics stock By Investing.com - Investing.com Canada
Cytokinetics stock holds $78 target from JMP amid trial results - Investing.com
CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus
Why These Two Biotech Stocks Just Diverged - Investor's Business Daily
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia
Raymond James maintains Cytokinetics stock with $81 target By Investing.com - Investing.com UK
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha
Cytokinetics CEO compensation jumps 64%, thanks in large part to stock awardsSan Francisco Business Times - The Business Journals
Cytokinetics CEO Makes Major Stock Move! - TipRanks
Former Gilead legal star departs Cytokinetics as crucial FDA ruling approachesSan Francisco Business Times - The Business Journals
Cytokinetics Inc Stock (CYTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):